-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
LivaNova PLC (NASDAQ:LIVN) Given Average Rating of "Buy" by Brokerages
LivaNova PLC (NASDAQ:LIVN) Given Average Rating of "Buy" by Brokerages
Shares of LivaNova PLC (NASDAQ:LIVN – Get Rating) have received a consensus recommendation of "Buy" from the six research firms that are presently covering the stock, Marketbeat reports. Five analysts have rated the stock with a buy rating. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $90.20.
Several analysts recently commented on the company. Needham & Company LLC decreased their price target on LivaNova from $106.00 to $88.00 and set a "buy" rating on the stock in a research note on Thursday, August 4th. StockNews.com raised LivaNova from a "hold" rating to a "buy" rating in a research note on Friday, September 9th. Finally, The Goldman Sachs Group decreased their price target on LivaNova from $85.00 to $73.00 and set a "buy" rating on the stock in a research note on Tuesday, August 16th.
Get LivaNova alerts:LivaNova Price Performance
Shares of NASDAQ:LIVN opened at $54.99 on Friday. LivaNova has a 1-year low of $53.28 and a 1-year high of $93.89. The firm has a market capitalization of $2.94 billion, a PE ratio of -98.20 and a beta of 0.91. The business's 50 day moving average is $60.85 and its 200-day moving average is $68.13. The company has a current ratio of 2.93, a quick ratio of 2.47 and a debt-to-equity ratio of 0.36.
LivaNova (NASDAQ:LIVN – Get Rating) last announced its quarterly earnings data on Wednesday, August 3rd. The company reported $0.53 earnings per share for the quarter, topping the consensus estimate of $0.51 by $0.02. The company had revenue of $254.20 million for the quarter, compared to analyst estimates of $249.55 million. LivaNova had a positive return on equity of 9.35% and a negative net margin of 2.74%. LivaNova's revenue for the quarter was down 3.9% compared to the same quarter last year. During the same quarter last year, the firm earned $0.52 EPS. Sell-side analysts predict that LivaNova will post 1.91 earnings per share for the current year.Institutional Investors Weigh In On LivaNova
A number of institutional investors and hedge funds have recently made changes to their positions in LIVN. Column Capital Advisors LLC raised its position in shares of LivaNova by 109.1% during the first quarter. Column Capital Advisors LLC now owns 345 shares of the company's stock worth $28,000 after acquiring an additional 180 shares during the last quarter. Northwestern Mutual Wealth Management Co. raised its position in shares of LivaNova by 29.7% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 787 shares of the company's stock worth $49,000 after acquiring an additional 180 shares during the last quarter. Wolverine Asset Management LLC bought a new stake in LivaNova in the second quarter valued at about $67,000. Meeder Asset Management Inc. bought a new stake in LivaNova in the first quarter valued at about $155,000. Finally, Blair William & Co. IL bought a new stake in LivaNova in the fourth quarter valued at about $212,000. Institutional investors own 98.89% of the company's stock.
LivaNova Company Profile
(Get Rating)
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.
Recommended Stories
- Get a free copy of the StockNews.com research report on LivaNova (LIVN)
- 3 Banks Worth Considering For Q4
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- MarketBeat: Week in Review 9/12 – 9/16
- No One Told These 3 Stocks It's a Down Week
- Is There a Cure for What is Ailing Teladoc Stock?
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.
Shares of LivaNova PLC (NASDAQ:LIVN – Get Rating) have received a consensus recommendation of "Buy" from the six research firms that are presently covering the stock, Marketbeat reports. Five analysts have rated the stock with a buy rating. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $90.20.
据市场报道，Liva Nova PLC(纳斯达克代码：LIVN-GET Rating)的股票已收到目前追踪该股票的六家研究公司一致给予的买入建议。五位分析师将该股的评级定为买入。在去年发布该股报告的券商中，12个月目标价的平均水平为90.20美元。
Several analysts recently commented on the company. Needham & Company LLC decreased their price target on LivaNova from $106.00 to $88.00 and set a "buy" rating on the stock in a research note on Thursday, August 4th. StockNews.com raised LivaNova from a "hold" rating to a "buy" rating in a research note on Friday, September 9th. Finally, The Goldman Sachs Group decreased their price target on LivaNova from $85.00 to $73.00 and set a "buy" rating on the stock in a research note on Tuesday, August 16th.
几位分析师最近对该公司发表了评论。8月4日，Needham&Company LLC将Liva Nova的目标价从106.00美元下调至88美元，并在一份研究报告中设定了该股的“买入”评级。在9月9日星期五的一份研究报告中，StockNews.com将LivaNova的评级从持有上调至买入。最后，高盛夫妇在8月16日星期二的一份研究报告中将Liva Nova的目标价从85.00美元下调至73.00美元，并对该股设定了买入评级。
LivaNova Price Performance
Liva Nova性价比
Shares of NASDAQ:LIVN opened at $54.99 on Friday. LivaNova has a 1-year low of $53.28 and a 1-year high of $93.89. The firm has a market capitalization of $2.94 billion, a PE ratio of -98.20 and a beta of 0.91. The business's 50 day moving average is $60.85 and its 200-day moving average is $68.13. The company has a current ratio of 2.93, a quick ratio of 2.47 and a debt-to-equity ratio of 0.36.
纳斯达克：livn的股价上周五开盘报54.99美元。LivaNova的一年低点为53.28美元，一年高位为93.89美元。该公司的市值为29.4亿美元，市盈率为-98.20，贝塔系数为0.91。该业务的50日移动均线切入位在60.85美元，200日移动均线切入位在68.13美元。该公司的流动比率为2.93，速动比率为2.47，债务权益比率为0.36。
Institutional Investors Weigh In On LivaNova
机构投资者对LivaNova的看法
A number of institutional investors and hedge funds have recently made changes to their positions in LIVN. Column Capital Advisors LLC raised its position in shares of LivaNova by 109.1% during the first quarter. Column Capital Advisors LLC now owns 345 shares of the company's stock worth $28,000 after acquiring an additional 180 shares during the last quarter. Northwestern Mutual Wealth Management Co. raised its position in shares of LivaNova by 29.7% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 787 shares of the company's stock worth $49,000 after acquiring an additional 180 shares during the last quarter. Wolverine Asset Management LLC bought a new stake in LivaNova in the second quarter valued at about $67,000. Meeder Asset Management Inc. bought a new stake in LivaNova in the first quarter valued at about $155,000. Finally, Blair William & Co. IL bought a new stake in LivaNova in the fourth quarter valued at about $212,000. Institutional investors own 98.89% of the company's stock.
一些机构投资者和对冲基金最近改变了他们在livn的头寸。Column Capital Advisors LLC在第一季度将其在Liva Nova股票的持仓提高了109.1%。Column Capital Advisors LLC在上个季度增持了180股后，现在拥有345股该公司股票，价值2.8万美元。西北互惠财富管理公司在第二季度将其持有的Liva Nova股票的仓位提高了29.7%。西北互惠财富管理公司目前持有该公司787股股票，价值49,000美元，该公司在上个季度增持了180股股票。金刚狼资产管理有限责任公司在第二季度购买了LivaNova的新股份，价值约6.7万美元。Meeder Asset Management Inc.在第一季度购买了LivaNova的新股份，价值约为155,000美元。最后，Blair William&Co.IL在第四季度购入了LivaNova的新股份，价值约为21.2万美元。机构投资者持有该公司98.89%的股票。
LivaNova Company Profile
Liva Nova公司简介
(Get Rating)
(获取评级)
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.
Liva Nova PLC是一家医疗设备公司，在全球设计、开发、制造和销售治疗解决方案。它通过三个部分运作：心肺、神经调节和高级循环支持。心肺部门开发、生产和销售心肺产品，包括氧合器、心肺机、自体输血系统、灌流管系统、套管、连接件和其他相关产品。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on LivaNova (LIVN)
- 3 Banks Worth Considering For Q4
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- MarketBeat: Week in Review 9/12 – 9/16
- No One Told These 3 Stocks It's a Down Week
- Is There a Cure for What is Ailing Teladoc Stock?
- 免费获取StockNews.com关于Liva Nova的研究报告(Livn)
- 第四季度值得考虑的3家银行
- 股市：红海中的三座强国
- MarketBeat：回顾一周9/12-9/16
- 没有人告诉这三只股票这是下跌的一周
- 有什么办法可以治愈Teladoc股票的问题吗？
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.
接受Liva Nova Daily的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯，接收Liva Nova和相关公司的最新新闻和分析师评级的每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧